Cargando…
C‐Jun N‐terminal kinase signalling pathway in response to cisplatin
Cisplatin (cis diamminedichloroplatinum II, cDDP) is one of the most effective cancer chemotherapeutic agents and is used in the treatment of many types of human malignancies. However, inherent tumour resistance is a major barrier to effective cisplatin therapy. So far, the mechanism of cDDP resista...
Autores principales: | Yan, Dong, An, GuangYu, Kuo, Macus Tien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082413/ https://www.ncbi.nlm.nih.gov/pubmed/27374471 http://dx.doi.org/10.1111/jcmm.12908 |
Ejemplares similares
-
Alarmins and c-Jun N-Terminal Kinase (JNK) Signaling in Neuroinflammation
por: Anfinogenova, Nina D., et al.
Publicado: (2020) -
c-Jun N-Terminal Kinase Signaling Inhibitors Under Development
por: Han, Sun-Young
Publicado: (2008) -
Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity
por: Nicholas, Brian D., et al.
Publicado: (2017) -
c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
por: Tian, Xiaodong, et al.
Publicado: (2021) -
Jun N-terminal kinase signaling makes a face
por: Hursh, Deborah A., et al.
Publicado: (2016)